Hansa Biopharma — Oktober 2024
-
"The ConfIdeS trial continues to progress following completed randomization in May and data from the study is expected to provide the basis for a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) in the second half of 2025."
-
"Conference Call Details
Hansa Biopharma will host a telephone conference today Thursday, October 17, 2024, at 14:00 CET / 8:00 am ET.
The event will be hosted by Søren Tulstrup, President and CEO, Evan Ballantyne, CFO, and Hitto Kaufmann, CR&DO. The call will include a review of the interim results and a business and pipeline update. It will be held in English."
-
Ifg. "Consensus model Total" herfra: (Analysts and consensus) https://www.hansabiopharma.com/investors/analysts/ rammer i vi oppe i intervallet mellem Median-High for 2024. Overslag: Revenue 188.6 (9M 2024) + 78.4 (Q4 2024 gæt) = 267 MSEK. Det er altså rigtigt fint.
-
Hansa Biopharma: Improved use of IDEFIRIX
-
Hansa Biopharma ökar omsättningen och minskar förlusten https://www.affarsvarlden.se/artikel/hansa-biopharma-okar-omsattning-och-minskar-forlusten
-
det var godt nok hurtigt aktien falder tilbage igen der er vist alt for mange lykkeridder inde som er kommet med på det massive fald aktien har haft og så er der os der har været med alt alt for længe med stadig kæmpe tab at tænke sig aktien har været oppe i 272 kr. for mindre end 4 år siden øv for vi stabile investorer
-
Det er da et super regnskab. Hvis man ser bort fra rabat-temaet, så er ligger omsætningen jo i top. Bliver Q4 på samme niveau bliver 2024 jo over højeste analytiker estimat. Der er kommet et nyt godkendt land til i Q3 (15 fra 14), Der er kommet 8 nye patienter til i Anti-GBM i Q3 og vi mangler kun 7 stk., som med lidt medvind kommer i Q4 (færdig før tid så). PAES kom der kun 3 nye patienter til i Q3, men stadig on track til færdiggørelse i 2025.
-
Conference Call - Hansa Biopharma will host a telephone conference today Thursday, October 17, 2024, at 14:00 CET / 8:00 am ET. :
Webcast | Interim Report for January – September 2024
Interim Report for January – September 2024
(event.choruscall.com)
Her kl. 14:00
-
Hansa Biopharma: Improved use of IDEFIRIX
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind